OncoMatch/Clinical Trials/NCT02143830
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Is NCT02143830 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for fanconi anemia.
Treatment: Busulfan · Cyclophosphamide · Fludarabine · rabbit ATG · G-CSF · Peripheral blood stem cell — The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or matched unrelated donors following a preparative regimen of busulfan, fludarabine, anti-thymocyte globulin and cyclophosphamide.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Demographics
Lab requirements
Kidney function
serum creatinine <1.5 mg/dl or if serum creatinine is outside the normal range, then crcl > 50 ml/min/1.73 m2
Liver function
< 5 x upper limit of normal (uln) alanine transaminase (alt) and < 2.0 mg/dl total serum bilirubin
Cardiac function
asymptomatic or if symptomatic then 1) left ventricular ejection fraction (lvef) at rest must be > 50% and must improve with exercise or 2) shortening fraction > 29%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
- Cincinnati Children's Hospital Medical Center · Cincinnati, Ohio
- Fred Hutchinson Cancer Research Center · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02143830 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify